1. Home
  2. BRSP vs RLMD Comparison

BRSP vs RLMD Comparison

Compare BRSP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrightSpire Capital Inc.

BRSP

BrightSpire Capital Inc.

HOLD

Current Price

$4.13

Market Cap

528.9M

Sector

Real Estate

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$3.86

Market Cap

461.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRSP
RLMD
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
528.9M
461.9M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
BRSP
RLMD
Price
$4.13
$3.86
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$6.50
★ $12.40
AVG Volume (30 Days)
★ 1.5M
1.1M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
★ 11.03%
N/A
EPS Growth
★ 75.24
45.28
EPS
★ N/A
N/A
Revenue
★ $330,587,000.00
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17.54
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$3.98
$1.78
52 Week High
$6.17
$8.00

Technical Indicators

Market Signals
Indicator
BRSP
RLMD
Relative Strength Index (RSI) 30.14 34.70
Support Level N/A $3.34
Resistance Level $6.04 $4.51
Average True Range (ATR) 0.13 0.23
MACD -0.02 -0.02
Stochastic Oscillator 21.50 21.21

Price Performance

Historical Comparison
BRSP
RLMD

About BRSP BrightSpire Capital Inc.

BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: